Table 2. Symptoms, comorbidities and severity of disease by age group, FFX study, Kisumu, Kenya, June-October 2020.
| Age Group (n/%) | |||||
|---|---|---|---|---|---|
| <25 | 25–54 | 55+ | Total | ||
| (n = 24) | (n = 115) | (n = 13) | (n = 152) | ||
| Severity of COVID-19 | Not hospitalized | 24 (100.0) | 92 (80.0) | 5 (38.5) | 121 (79.6) |
| Hospitalized but no ICU | 0 (0.0) | 18 (15.7) | 6 (46.2) | 24 (15.8) | |
| ICU without death | 0 (0.0) | 3 (2.6) | 1 (7.7) | 4 (2.6) | |
| Death | 0 (0.0) | 2 (1.7) | 1 (7.7) | 3 (2.0) | |
| Symptom prevalence | Asymptomatic | 11 (45.8) | 35 (30.4) | 1 (7.7) | 47 (31.6%) |
| Any symptom | 13 (54.2) | 80 (69.6) | 12 (92.3) | 105 (69.0) | |
| 1–3 symptoms | 10 (41.7) | 13 (16.3) | 4 (30.8) | 38 (25.7%) | |
| 4+ symptoms | 3 (12.5) | 56 (48.7) | 8 (61.5) | 67 (43.4%) | |
| Fever or cough or fatigue* | 6 (25.0) | 64 (55.7) | 9 (69.2) | 79 (52.0%) | |
| Specific symptoms | Cough | 6 (25.0) | 49 (42.6) | 8 (66.7) | 63 (60.0) |
| Headache | 4 (16.7) | 49 (42.6) | 5 (41.7) | 58 (55.2) | |
| Fever / chills | 4 (16.7) | 46 (40.0) | 6 (50.0) | 56 (53.3) | |
| Loss of appetite | 4 (16.7) | 38 (33.0) | 8 (66.7) | 50 (47.6) | |
| Fatigue | 1 (4.2) | 40 (34.8) | 6 (50.0) | 47 (44.8) | |
| Loss of smell/taste | 5 (20.1) | 38 (33.0) | 3 (25.0) | 46 (43.8) | |
| Sore throat | 3 (12.5) | 34 (29.6) | 5 (41.7) | 42 (40.0) | |
| Muscle/Joint aches | 2 (8.3) | 28 (24.3) | 7 (58.3) | 37 (35.2) | |
| Runny nose | 6 (25.0) | 23 (20.0) | 3 (25.0) | 32 (30.5) | |
| Shortness of breath | 0 (0.0) | 22 (19.1) | 2 (16.7) | 24 (22.9) | |
| Diarrhea | 4 (16.7) | 19 (16.5) | 1 (8.3) | 24 (22.9) | |
| Other symptoms | 1 (4.2) | 12 (10.4) | 3 (25.0) | 16 (15.2) | |
| Comorbidity prevalence | None | 21 (87.5) | 80 (69.6) | 4 (30.8) | 105 (69.1) |
| Any comorbidity | 3 (12.5) | 35 (30.4) | 9 (69.2) | 47 (30.9) | |
| 1 only | 2 (66.7) | 25 (71.4) | 3 (33.3) | 30 (63.8) | |
| 2+ | 1 (33.3) | 10 (28.6) | 6 (66.7) | 17 (36.2) | |
| Non-communicable comorbidities and risk factors | Underweight | 0 (0.0) | 1 (1.9) | 0 (0.0) | 1 (0.7) |
| Overweight/Obese | 1 (4.2) | 26 (22.6) | 3 (23.1) | 30 (19.7) | |
| Diabetes | 0 (0.0) | 7 (6.1) | 7 (53.9) | 14 (9.2) | |
| Asthma | 1 (4.2) | 4 (3.5) | 0 (0.0) | 3 (2.0) | |
| Heart Disease | 0 (0.0) | 1 (0.9) | 1 (7.7) | 2 (1.3) | |
| Chronic lung disease | 0 (0.0) | 2 (1.7) | 0 (0.0) | 0 (0.0) | |
| Cancer | 0 (0.0) | 0 (0.0) | 1 (7.7) | 1 (0.7) | |
| Other | 0 (0.0) | 13 (34.3) | 5 (38.5) | 20 (13.2) | |
| Infectious comorbidities** | HIV | 1 (4.2) | 14 (12.2) | 2 (15.4) | 17 (11.2) |
| Newly diagnosed | 0 (0.0) | 1 (6.7) | 0 (0.0) | 1 (5.9) | |
| On ART | 1 (100) | 10 (71.4) | 2 (100) | 13 (76.5) | |
| Not on ART | 0 (0.0) | 3 (21.4) | 0 (0.0) | 3 (17.6) | |
| Tuberculosis | 1 (4.2) | 0 (0.0) | 1 (0.7) | 1 (0.7) | |
| Malaria | 0 (0.0) | 3 (0.0) | 0 (0.0) | 3 (0.0) | |
*Most common symptoms of COVID-19 reported globally (https://www.who.int/emergencies/diseases/novel-coronavirus-2019)
**Further testing for the presence of infectious diseases including Leptospirosis, Dengue, Influenza, Respiratory Syncytial Virus (RSV) and Chikungunya all tested negative by polymerase chain reaction (PCR) testing